NHEJ inhibitor-1

NHEJ Inhibitor-1 (Compound C2), a trifunctional Pt (II) complex, mitigates non-homologous end joining (NHEJ) /homologous recombination (HR) -related double strand break (DSB) repairs, combating Cisplatin resistance in non-small cell lung cancer (NSCLC) . It achieves this by inhibiting the damage repair proteins Ku70 and Rad51, thus re-sensitizing tumors to Cisplatin. Additionally, this compound prompts the generation of reactive oxygen species (ROS) and reduces mitochondrial membrane potential (MMP) [1].